Efficacy and safety of Lutetium-177 (177Lu)-PSMA-617 in metastatic Castration-Resistant prostate cancer patients with superscan pattern: A retrospective cohort study
{{output}}
Background: Lutetium-177 (177Lu)-PSMA-617, a targeted radioligand therapy, has demonstrated significant survival benefits in patients with metastatic castration-resistant prostate cancer (mCRPC). Its application in patients with ... ...
